Braveheart Bio is a pre-revenue biotech where insiders bought $159M (8.823% of market cap), but the shares are in a downtrend, quality is below the engine's floor and the latest quarter missed badly.
Thesis pillars
- Binary Biotech Risk→Stable
- Heavy Insider Buying→Stable
- Latest Quarter Miss→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Oct 11, 2026
Braveheart Bio, Inc. (BRVE) Stock Analysis
Range Bound setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $20.11: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 6.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin... Read more
Sell if holding. Engine safety override at $20.11: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 6.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: RSI 54 mid-range, Bollinger mid-band. Score 5.6/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 7d<=7d. Suitability: speculative.
Recent developments
updated Oct 30, 2026Recent Developments — Braveheart Bio, Inc.
Latest news
- NEWS Braveheart Bio Announces Upcoming Presentations and Investor Webinar for BHB-1893 — fiscal.ai Oct 30, 2026 neutral
- NEWS Braveheart Bio Announces Late-breaking Presentation Of 52-Week Extension Data For BHB-1893 In Obstructive HCM At The Ame — benzinga Oct 30, 2026 positive
- NEWS Cantor Fitzgerald Maintains Overweight Rating on Braveheart Bio — fiscal.ai Oct 20, 2026 positive
- NEWS Cantor Fitzgerald Reiterates Overweight on Braveheart Bio, Maintains $40 Price Target — benzinga Oct 20, 2026 positive
- NEWS Braveheart Bio Q2 EPS $(2.51) — benzinga Sep 8, 2026 negative
Latest item Oct 30, 2026 · Generated 2026-11-05T11:49:09Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $20.11: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 6.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: RSI 54 mid-range, Bollinger mid-band. Prior stop was $18.70. Score 5.6/10, moderate confidence.
Analyst target: $38.46 (+91.3% upside). Prior stop was $18.70. Stop-loss: $18.70.
Quality below floor (2.5 < 4.0).
Braveheart Bio, Inc. trades at a P/E of N/A (forward -10.1). TrendMatrix value score: 9.0/10. Verdict: Sell.
11 analysts rate BRVE, with a consensus score of 4.3/5. 4 analysts publish price targets averaging $45.
What does Braveheart Bio, Inc. do?Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with...
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.